EUROMEDICA  Hanover 6-7  Juni 2008	Advanced methods of diagnosis, treatment and prophylactics
	European Academy of Natural Sciences, Hanover European Scientific Society, Hanover Russian Academy of Natural Sciences, Moscow

Home

Abstracts

Contact

Disclaimer

Acute respiratory viral infections present a serious problem for health care all over the globe due to their commonness and significant social-economic damage caused by them. Thus general amount of diseased in Russia annually exceeds 20 mln people and casualties from influenza and its complications are recorded between 0,5 and 2,5% or even more. It is known that respiratory illnesses suppress the immune system of a diseased person, therefore the study of the mechanisms of interferon synthesis and other cytokines enables a deeper understanding of the role of the immune system on the different stages of infection process including development and research of new preparations produced from ecologically clean natural raw materials and influencing on reproduction of influenza viruses as well as stimulating the general and local immune system. This work presents the results of investigation of a new preparation that is a border water layer (Avoda, RF Certificate Nr. 7688306). It studies Avoda’s influence on survival and proliferation of 10 various human intertwined cellular lines. It was shown that proliferation of some of them (cervical carcinoma - HeLa, carcinoma of larynx – Hep-2, leukemia L 41, human liver – Chang liver) is suppressed under the action of Avoda. Experiments aimed at research of Avoda’s action on alteration of genes transcription of regular cytokines in human cells showed that its administration changed cytokine profile in cells. As the result of treatment with Avoda enabled to detect additionally the activity of mRNA IFNs-γ or IL-2 (cytokines of the 1^st type), IL-6 (cytokines of the 2^nd type), IL-18 (participating in launch of synthesis IFNs-γ) or IL-8. Consequently under Avoda influence cytokine profile in the cells in accordance with type T1- and T2. Quite probable that this regulatory influence raises the efficiency of the immune protection and can protect the cell from external exposures. In vitro studies on the model of a diploid line of human derma-muscle cells (M7) infected with influenza virus H3N2 in the dose 100 CCID50₅₀ followed in 24 hours by Avoda administration (1:2) displayed suppression of the hemagglutinin titre by 2,5 log₂ /ml. It was shown that Avoda renders not only direct antivirus action towards virus of influenza but also modulates cytokine response under infection of the virus. In other words we observed a inhibited action of Avoda in regard to proliferation of influenza virus in cells M-7 due to activation of gene expression IL-2 and IL-12 (T1) as well as IL-4, IL-6, IL-10 (T2) and cytokines with antivirus action (IFNs -α, TNF -α). The research of potential Avoda therapeutic effect against influenza and respiratory infections revealed that the examined patients were sensible to the preparation in 75-80% cases. The researches showed a possibility of applying Avoda individually for each patient to treat influenza and respiratory infections. The obtained data is feasible for estimating Avoda as a substance with manifested antiinfluenza activity.